|Videos|October 7, 2022
Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer
In a recent OncLive® Scientific Interchange moderated by David R. Gandara, MD, experts discussed the prevalence and pathobiology of SCLC cases in their practices; the role of surgery, radiation, prophylactic cranial irradiation (PCI), and systemic therapy in LS-SCLC; and optimal systemic approaches for ES-SCLC in the first-line and relapsed settings.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5

































